CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $90.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price target increased by Citigroup from $88.00 to $90.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Wells Fargo & Company reduced their target price on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday. UBS Group assumed coverage on shares of CRISPR Therapeutics in a report on Thursday, October 15th. They issued a “neutral” rating and a $52.00 target price on the stock. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Finally, William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.69.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded up $1.51 during mid-day trading on Wednesday, hitting $50.07. The company’s stock had a trading volume of 1,234,187 shares, compared to its average volume of 1,494,760. The company has a market capitalization of $4.84 billion, a price-to-earnings ratio of -10.56 and a beta of 1.92. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $63.45. The stock has a fifty day moving average of $53.28 and a 200-day moving average of $52.81.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The company had revenue of $12.67 million for the quarter, compared to analyst estimates of $14.75 million. The firm’s revenue for the quarter was up 1311.1% compared to the same quarter last year. As a group, equities analysts forecast that CRISPR Therapeutics will post -4.49 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the sale, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at $15,526,332.22. This represents a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This represents a 48.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Compass Financial Management LLC bought a new stake in shares of CRISPR Therapeutics during the third quarter worth $25,000. Versant Capital Management Inc boosted its holdings in CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in CRISPR Therapeutics in the second quarter worth about $56,000. GAMMA Investing LLC raised its holdings in CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after purchasing an additional 597 shares during the last quarter. Finally, Hollencrest Capital Management raised its holdings in CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after purchasing an additional 937 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target on CRISPR Therapeutics, a potentially supportive signal for investor sentiment; the report did not provide the new target in the available details. Citigroup price target report
• Positive Sentiment: Brookline Capital Markets substantially improved its forecasts, revising projected losses to $4.74 per share for FY2026 from $5.63 and to $3.83 for FY2027 from $4.51. HC Wainwright also made smaller upward adjustments to several quarterly and annual estimates and maintains a Buy rating. Better-than-previous forecasts could support the shares, although losses remain expected. Brookline Capital Markets comments CRISPR Therapeutics analyst estimates
• Neutral Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, indicating a more cautious view than the Buy calls but not a direct downgrade. RBC Capital Hold rating
• Neutral Sentiment: CRSP is attracting increased attention among Zacks.com users, but the “trending stock” coverage does not itself report a new business or clinical development. Zacks trending-stock article

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.